Skip to content

Author

Hiroyuki Gatanaga

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Safety and Efficacy of Doravirine/Islatravir (100 mg/0.25 mg) Once Daily after Islatravir Dose Reduction from 0.75 mg: Week 96 Results from an Open-Label Phase 3 Study in Adults with HIV-1.

BACKGROUND Once-daily doravirine/islatravir (DOR/ISL 100 mg/0.25 mg) demonstrated non-inferior efficacy and comparable safety to continuing prior antiretroviral therapy in two phase 3 studies of virologically suppressed adults with HIV-1. We assessed the safety and efficacy of DOR/ISL (100 mg/0.25 mg) in participants w...

R. Mngqibisa, S. Kassim, Cheryl McDonald et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.